Related Experiment Video
Updated: Nov 30, 2025
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.2K
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
John D Gordan1, Erin B Kennedy2, Ghassan K Abou-Alfa3
1University of California, San Francisco, San Francisco, CA.
Summary
This guideline recommends atezolizumab plus bevacizumab as a first-line treatment for advanced hepatocellular carcinoma (HCC). It also details second-line therapy options and alternative first-line treatments for specific patient groups.
Area of Science:
- Hepatobiliary Oncology
- Clinical Practice Guidelines
- Systemic Therapy
Background:
- Advanced hepatocellular carcinoma (HCC) presents complex treatment challenges.
- Systemic therapy is crucial for managing advanced HCC.
- Evidence-based guidelines are needed for optimal clinical decision-making.
Purpose of the Study:
- To develop an evidence-based clinical practice guideline for advanced HCC.
- To assist clinicians in making informed treatment decisions.
- To provide updated care options for patients with advanced HCC.
Main Methods:
- Systematic review of phase III randomized controlled trials (2007-2020).
- Expert Panel convened by ASCO.
- Inclusion criteria focused on systemic therapy for advanced HCC.
Main Results:
- Nine phase III trials met the inclusion criteria.
- Atezolizumab + bevacizumab recommended as first-line therapy for eligible patients.
- Details provided on alternative first-line and various second-line therapy options, including tyrosine kinase inhibitors and immunotherapy.
Conclusions:
- Atezolizumab + bevacizumab is a primary first-line option for advanced HCC.
- Multiple second-line treatment strategies are available based on prior therapy and patient factors.
- The guideline offers comprehensive recommendations for advanced HCC management.
Related Concept Videos
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
02:57Targeted Cancer Therapies
8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.2K
02:49Cancer Therapies
9.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.3K
01:27Tumor Immunotherapy
955
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
955
01:29Chronic Pancreatitis II: Collaborative Care
192
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
192
01:21Hepatic Portal System
4.3K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
4.3K